SWX:BSLN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. More Details


Snowflake Analysis

High growth potential and slightly overvalued.


Similar Companies

Share Price & News

How has Basilea Pharmaceutica's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BSLN is not significantly more volatile than the rest of Swiss stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: BSLN's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

5.0%

BSLN

3.6%

CH Biotechs

0.4%

CH Market


1 Year Return

-6.2%

BSLN

1.3%

CH Biotechs

-0.4%

CH Market

Return vs Industry: BSLN underperformed the Swiss Biotechs industry which returned 1.3% over the past year.

Return vs Market: BSLN underperformed the Swiss Market which returned -0.4% over the past year.


Shareholder returns

BSLNIndustryMarket
7 Day5.0%3.6%0.4%
30 Day3.2%1.5%2.8%
90 Day8.3%2.0%5.8%
1 Year-6.2%-6.2%2.6%1.3%3.1%-0.4%
3 Year-30.3%-30.3%4.3%1.9%19.8%4.7%
5 Year-30.1%-30.1%71.8%66.0%51.9%26.8%

Long-Term Price Volatility Vs. Market

How volatile is Basilea Pharmaceutica's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Basilea Pharmaceutica undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BSLN (CHF54.35) is trading below our estimate of fair value (CHF237.46)

Significantly Below Fair Value: BSLN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BSLN is poor value based on its PE Ratio (198.3x) compared to the XE Biotechs industry average (43.3x).

PE vs Market: BSLN is poor value based on its PE Ratio (198.3x) compared to the Swiss market (24.5x).


Price to Earnings Growth Ratio

PEG Ratio: BSLN is poor value based on its PEG Ratio (3.3x)


Price to Book Ratio

PB vs Industry: BSLN has negative assets, so we can't compare its PB Ratio to the CH Biotechs industry average.


Next Steps

Future Growth

How is Basilea Pharmaceutica forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

60.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BSLN's forecast earnings growth (60.9% per year) is above the savings rate (-0.3%).

Earnings vs Market: BSLN's earnings (60.9% per year) are forecast to grow faster than the Swiss market (13% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: BSLN's revenue (20.5% per year) is forecast to grow faster than the Swiss market (4.6% per year).

High Growth Revenue: BSLN's revenue (20.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BSLN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Basilea Pharmaceutica performed over the past 5 years?

30.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BSLN has a large one-off gain of CHF15.0M impacting its June 30 2020 financial results.

Growing Profit Margin: BSLN became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: BSLN has become profitable over the past 5 years, growing earnings by 30.5% per year.

Accelerating Growth: BSLN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: BSLN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (7.3%).


Return on Equity

High ROE: BSLN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Basilea Pharmaceutica's financial position?


Financial Position Analysis

Short Term Liabilities: BSLN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: BSLN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: BSLN has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: BSLN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.

Debt Coverage: BSLN's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if BSLN's interest payments on its debt are well covered by EBIT.


Balance Sheet


Next Steps

Dividend

What is Basilea Pharmaceutica current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BSLN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BSLN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BSLN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BSLN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: BSLN is not paying a notable dividend for the Swiss market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BSLN's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.4yrs

Average management tenure


CEO

David Veitch (55 yo)

2.75yrs

Tenure

CHF1,432,037

Compensation

Mr. David Veitch has been the Chief Executive Officer of Basilea Pharmaceutica Ltd. since April 19, 2018 and Basilea Pharmaceutica International Ltd., since September 1, 2014. Mr. Veitch served as the Pres...


CEO Compensation Analysis

Compensation vs Market: David 's total compensation ($USD1.61M) is above average for companies of similar size in the Swiss market ($USD1.17M).

Compensation vs Earnings: David 's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
David Veitch
Chief Executive Officer2.75yrsCHF1.43m0.012%
CHF 70.6k
Adesh Kaul
Chief Financial Officer1.75yrsno data0.0046%
CHF 27.2k
Gerrit Hauck
Chief Technology Officer2.67yrsno datano data
Laurenz Kellenberger
Chief Scientific Officer12yrsno data0.0046%
CHF 27.2k
Marc Engelhardt
Chief Medical Officer3yrsno datano data
Peer Schröder
Head of Corporate Communications & Investor Relationsno datano datano data
Damian Heller
General Counsel & Corporate Secretary3.42yrsno datano data
Ursula Eberhardt
Head of Global Human Resources4yrsno datano data
Lutz Wevelsiep
Head of Regulatory Affairs15yrsno datano data
Dietrich Stüber
Head of Internal Servicesno datano datano data
Cornelia Blaettchen
Head of Business Development & Licensing15yrsno datano data
Malcolm Page
Head of Biologyno datano datano data

3.4yrs

Average Tenure

55yo

Average Age

Experienced Management: BSLN's management team is considered experienced (3.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Nicole Onetto
Independent Non-Executive Director3.75yrsCHF186.88kno data
Domenico Scala
Independent Chairman of the Board4.75yrsCHF329.94k0.0036%
CHF 21.2k
Alf Gunnar Nicklasson
Independent Non-Executive Director7.75yrsCHF230.17kno data
Ronald Scott
Director2.75yrsCHF130.69k0.072%
CHF 421.2k
Steven Skolsky
Independent Non-Executive Director12.83yrsCHF192.13kno data
Thomas Werner
Independent Vice-Chairman3yrsCHF216.92kno data

4.3yrs

Average Tenure

64.5yo

Average Age

Experienced Board: BSLN's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Basilea Pharmaceutica AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Basilea Pharmaceutica AG
  • Ticker: BSLN
  • Exchange: SWX
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CHF587.155m
  • Shares outstanding: 10.80m
  • Website: https://www.basilea.com

Number of Employees


Location

  • Basilea Pharmaceutica AG
  • Grenzacherstrasse 487
  • Basel
  • Basel-Stadt
  • 4058
  • Switzerland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BPMU.FOTCPK (Pink Sheets LLC)YesRegistered SharesUSUSDMar 2004
BSLNSWX (SIX Swiss Exchange)YesRegistered SharesCHCHFMar 2004
PK5DB (Deutsche Boerse AG)YesRegistered SharesDEEURMar 2004
0QNALSE (London Stock Exchange)YesRegistered SharesGBCHFMar 2004

Biography

Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It of...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/16 18:12
End of Day Share Price2021/01/15 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.